ALZAMEND NEURO, INC. Increase (Decrease) in Prepaid Expense
ALZAMEND NEURO, INC. (ALZN) reported Increase (Decrease) in Prepaid Expense of -$739.92 thousand for the 12-month period ending 2023-04-30, per its 10-K filed 2023-07-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2023-07-27
- ALZAMEND NEURO, INC. increase (decrease) in prepaid expense for fiscal 2023 was -$739.92K.
| Period end | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|
| 2023-04-30 | -$739.92K 10-K · filed 2023-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |